Osteoporosis Market Poised for Steady Growth

As the global population grows older, age-related diseases and conditions will become increasingly profitable for companies.

Case in point: The market for osteoporosis is set to swell 5.4% annually across seven major markets (7MM*) over the next nine years, according to GlobalData. The market’s value is forecast to rise from $10.5 billion in 2023 to $17.9 billion in 2033, fueled by the popularity of expensive anabolic therapies and increasing patient population sizes, the company predicts.
 
A metabolic bone disorder, osteoporosis increases fracture risk in the spine, hip, and forearm, often leading to prolonged recovery and full-time care. With longer lifespans, its prevalence is expected to rise, necessitating a greater focus on bone health management and proactive risk mitigation.
 
“Anabolic therapies stimulate bone formation and play a crucial role in osteoporosis,” GlobalData Pharma Analyst Sulayman Patel said. “Despite their higher cost over traditional bisphosphonates, their effectiveness in enhancing bone density justifies their increasing adoption. This shift reflects a broader trend in healthcare towards prioritizing outcomes over initial costs. However, balancing affordability and accessibility with clinical efficacy remains a challenge that pharmaceutical companies must continue to navigate.”
 
The osteoporosis market has historically been dominated by bisphosphonates, however, GlobalData forecasts that anabolic therapies, including Eli Lilly’s Forteo and Amgen’s Evenity, will gain market share, as more patients switch to anabolic therapies.  
 
“Osteoporosis is frequently undiagnosed until a fracture, complicating early detection and intervention. Improved diagnostic tools are crucial due to asymptomatic fractures, which often occur, underscoring the need for early detection to reduce osteoporosis morbidity through preventative measures, potentially utilizing machine learning to analyze large patient datasets for fracture risk factors,” Patel stated.
 
Integrating machine learning algorithms in diagnostics could significantly advance early detection by analyzing large patient datasets for patterns and risk factors, particularly following the U.S. Food and Drug Administration approval of Avicenna.AI’s CINA-VCF and 16 Bit’s Rho. These tools are designed to enhance the precision and effectiveness of osteoporosis diagnosis and fracture detection.
 
“While steady growth is projected for the osteoporosis landscape, there are several barriers expected to slow the expansion of the market during the forecast period. Primarily, the loss of patent protection for several drugs, such as Evenity, will lead to the launch of more generics and biosimilars,” Patel noted. “Additionally, low compliance with many osteoporosis drugs due to disruptive therapy regimens or adverse side effects will continue to limit market growth.” 
 
* 7MM: The United States, France, Germany, Italy, Spain, the United Kingdom, and Japan.